Wells Fargo analyst Derek Archila lowered the firm’s price target on Blueprint Medicines (BPMC) to $151 from $153 on slightly lower estimates, while keeping an Overweight rating on the shares. The firm remains bullish on shares as it expects an above-consensus guide for Ayvakit for FY25 plus POS BLU-808 Ph1 data in early 2025 to offer upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines Reports Strong Q3 2024 Results
- Blueprint management moves maybe made with buyer in mind, says Oppenheimer
- Blueprint Medicines reports Q3 EPS (89c), consensus (96c)
- Blueprint Medicines sees FY24 global AYVAKIT net product revenues $475M-$480M
- BPMC Upcoming Earnings Report: What to Expect?